ELVN Enliven Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why ELVN matters now
Enliven Therapeutics, Inc. (ELVN) is a US stock in Healthcare. The latest InvestLog snapshot shows $61.15 with +2.22% on the session and $4.37B in market capitalization; recent performance reads 1-month +12.27% and YTD +192.86%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-23.6M, and EPS of $-0.38. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.4%.
The latest indexable market news headline is "Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says" from Benzinga.
Additional event context on this page matters because analyst consensus is Buy with a median target of $61.00; recent insider activity includes ORBIMED ADVISORS LLC filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.25
P/S
0.00
EV/EBITDA
-26.53
DCF Value
$1.70
FCF Yield
-2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-21.0%
ROA
-21.2%
ROIC
-25.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-23.6M | $-0.38 |
| Q4 2025 | $0.00 | $-29.7M | $-0.45 |
| FY 2025 | $0.00 | $-103.7M | $-1.83 |
| Q3 2025 | $0.00 | $-20.1M | $-0.32 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$65.25
Target (Median)
$61.00
Target Range
$59.00 - $80.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.40
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.